Biomarkers of CASH

Active, not recruitingOBSERVATIONAL
Enrollment

1,040

Participants

Timeline

Start Date

May 22, 2020

Primary Completion Date

April 30, 2025

Study Completion Date

June 30, 2026

Conditions
Cerebral Cavernous MalformationCavernous AngiomaHemorrhagic Microangiopathy
Interventions
OTHER

observational

There is no intervention for any group in this observational study.

Trial Locations (4)

55905

Mayo Clinic, Rochester

60637

The University of Chicago Medical Center, Chicago

85013

Barrow Neurological Institute at St. Joseph's Hospital and Medical Center, Phoenix

94117

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Mayo Clinic

OTHER

collaborator

University of California, San Francisco

OTHER

collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

collaborator

Barrow Neurological Institute

OTHER

lead

University of Chicago

OTHER

NCT04467489 - Biomarkers of CASH | Biotech Hunter | Biotech Hunter